Latest News - AbbVie
Top Corporates Hub
AbbVie
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy
07.10.2026 07:39
Ironwood Pharmaceuticals' Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029. See why IRWD stock is a Buy now.
Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?
07.10.2026 07:16
Genmab stock: what the latest trial results mean for investors Genmab (CPSE:GMAB) is suddenly back on many watchlists after two fresh clinical readouts in oncology, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B cell lymphoma. The EPCORE DLBCL 2 trial, run with AbbVie, reported that epcoritamab plus R CHOP cut the risk of disease progression or death by 51% versus R CHOP alone in patients with higher risk DLBCL. For a late stage blood cancer study, that kind of...
AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%
07.10.2026 05:12
AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The combination reduced the risk of disease progression or death by 51% versus standard R-CHOP alone, improving progression-free survival. The trial is the first Phase 3 study to show a meaningful benefit from a bispecific antibody in the frontline DLBCL setting. The epcoritamab and R-CHOP Phase 3 win in newly diagnosed DLBCL comes against a wider context...
AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%
07.10.2026 05:12
AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The combination reduced the risk of disease progression or death by 51% versus standard R-CHOP alone, improving progression-free survival. The trial is the first Phase 3 study to show a meaningful benefit from a bispecific antibody in the frontline DLBCL setting. The epcoritamab and R-CHOP Phase 3 win in newly diagnosed DLBCL comes against a wider context...
AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?
07.10.2026 00:33
AbbVie Inc. (NYSE:ABBV) was trading at around $263 on October 5, up 14.18% over twelve months. Its payout ratio is 190.40%. The company distributes nearly twice what it reports as profit. A dividend that large is either about to be cut or is being paid out of something the earnings line does not show. READ […]
Forget Bonds: How Retirees Collect $6,650 a Month From Dividends Alone
06.10.2026 18:43
Treasuries now offer a yield that dividend investors once bragged about, which raises a question most retirees avoid asking: does an equity income portfolio actually come out ahead after risk, taxes, and inflation are factored in?
Genmab’s Lymphoma Bet Delivers a 51% Knockout
06.10.2026 16:39
The Danish biotech surged after its AbbVie-partnered Epkinly combination sharply reduced the risk of progression or death in newly diagnosed lymphoma patients.
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
06.10.2026 15:42
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Genmab: Epkinly Shines In Phase 3 DLBCL Trial
06.10.2026 15:05
Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Click for more on GMAB stock.
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
06.10.2026 14:31
Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
06.10.2026 14:22
ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.
Should You Buy AbbVie Stock Before Oct. 30?
06.10.2026 14:10
The healthcare company will release its third-quarter numbers later this month.
$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely
06.10.2026 12:49
When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible moment. Five companies have raised their dividends through every recession and rate shock in modern memory, and together they turn a single portfolio into a reliable cash machine.
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
06.10.2026 12:30
The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News
06.10.2026 12:25
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
Scotiabank Maintains Sector Outperform on AbbVie, Raises Price Target to $320
06.10.2026 08:45
Scotiabank analyst Louise Chen maintains AbbVie (NYSE:ABBV) with a Sector Outperform and raises the price target from $280 to $320.
Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk
06.10.2026 07:52
Investing.com -- Shares of Genmab surged more than 8% in early trading Tuesday after the Danish biotech and AbbVie said their combination treatment for newly diagnosed patients with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
06.10.2026 07:48
Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
AbbVie Announced Its 340B Rebate Pilot on October 2. Here’s What It Means for the Stock Before Vraylar’s 2027 Medicare Price Cut
05.10.2026 08:08
Key Stats for AbbVie StockCurrent Price: $262. 82Target Price (Mid): ~$362Street Target: ~$279Potential Total Return: ~38%Annualized IRR: ~8% / yearWhat Happened?AbbVie (ABBV:NYSE) has two pricing events landing on the same day.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
04.10.2026 02:46
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it off and […]